Research programme: respiratory syncytial virus infections - Arana Therapeutics

Drug Profile

Research programme: respiratory syncytial virus infections - Arana Therapeutics

Alternative Names: EGX-220; Research programme: RSV infections - Arana Therapeutics

Latest Information Update: 24 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EvoGenix
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 06 Mar 2007 Antibody is still in development for respiratory syncytial virus in Australia.
  • 08 Mar 2006 Preclinical trials in Respiratory syncytial virus infections in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top